Address
950 Towerview Lane
Suire 390
Foster City, CA
94404, United States
Contact
Zhengtu Yuan+1(415) 710-5481
zyuan@micurx.com
Website
Contezolid and contezolid acefosamil
Next generation oral and IV oxazolidinone with improved safety to treat methicillin-resistant S. aureus (MRSA)
Reduced risk of myelosuppression was shown in both preclinical & clinical studies including a Phase3 registration study in complicated skin infections
Technology:
Microorganisms:
Application:
Development stage:
- Antimicrobial compound/strategy
- Infection prevention
- Antimicrobial stewardship
- Microbial diagnostics
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Development
- Marketed product
- Research
- Validation
- Market entry
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Joint Venture
- Sell
- Outsource
Funding organisation:
- CARB-X
- FIND
- GARDP
- REPAIR
- OTHER / NA
Infectious disease area:
- UTI
- BSI
- RTI
- SSTI
- IAI
- SSI
- STI
- GII
- CNSI
Geographic origin:
- North America
- South America
- Eurasia
- Africa
- Oceania
Contezolid (oral), contezolid acefosamil (intravenous) and MRX-8 (intravenous) are available for licensing and/or co-development outside of greater China.
Pharmaceutical development and commericalization company focused on antibiotics and rare diseases
Next generation intravenous polymyxin to treat multidrug-resistant Gram-negative infections with the potential for reduced nephtrotoxicity, while maintaining excellent efficacy.
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!